Mabeza, Orlando D.

HRN: 25-63-82  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/10/2024
CEFTRIAXONE 1G (VIAL)
08/10/2024
08/17/2024
IV
2g
Q24
Urosepsis
Waiting Final Action 
08/11/2024
CIPROFLOXACIN 500MG (TAB)
08/11/2024
08/17/2024
ORAL
500mg
BID
UTI
Waiting Final Action 
08/11/2024
CIPROFLOXACIN 500MG (TAB)
08/11/2024
08/17/2024
ORAL
500mg
BID
UTI
Waiting Final Action 
08/14/2024
METRONIDAZOLE 500MG (TAB)
08/14/2024
08/21/2024
PO
500mg
TID
AGE
Waiting Final Action 
08/17/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
08/17/2024
08/24/2024
IV
500
Q8
Giardiasis
Waiting Final Action 
08/17/2024
CEFTRIAXONE 1G (VIAL)
08/17/2024
08/20/2024
IV
2g
OD
CAP
Waiting Final Action 
08/18/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
08/18/2024
08/24/2024
IV
500
Q8
Giardiasis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: